- CEO
- Howard Cass
- Full Time Employees
- 2
- Sector
- Real Estate
- Industry
- Real Estate - Services
- Address
- 777 Brickell Avenue Miami FL United States of America 33131
- IPO Date
- May 14, 1998
- Business
- Agritek Holdings, Inc. (AGTK) operates as an investor and distributor in the legal cannabis and hemp sector, focusing on real estate holdings, branded products, and related infrastructure. The company produces and distributes hemp-derived products under brands including Hemp Pops, MD Vapes, Rehab Rx, Higher Society, and California Premiums; product categories encompass human ingestibles such as tinctures, capsules, and gummies, CBD edibles, topicals, and pet products, offered through e-commerce sites like RehabRx.com and Hemppops.com as well as third-party retailers and brick-and-mortar stores. It provides business services to cannabis operators, including operational and compliance consulting, funding and financing solutions, dispensary and retail support, commercial production equipment build-outs, multichannel supply chains, consumer product development, and branding, marketing, and sales assistance; additionally, Agritek acquires and leases real estate properties such as cultivation facilities and dispensaries to licensed marijuana growers and operators.
Agritek maintains operations across the United States, including Florida, Colorado, and California, with historical activities noted in Washington State, Canada, and Puerto Rico. Founded in 1997 and headquartered at 777 Brickell Avenue in Miami, Florida, the company, formerly known as MediSwipe Inc., reoriented toward cannabis investments following its name change in April 2014.
Recent developments reflect strategic consolidation in hemp and cannabis branding, with key acquisitions including the 2020 purchase of assets, distribution rights, and brands from Apex Extractions to launch the Higher Society premium line featuring concentrates, extracts, tinctures, flower, topicals, edibles, rosin, vape pens, and accessories; the completion of acquiring Full Spectrum Biosciences Inc. as a wholly owned subsidiary to bolster IP formulations, blockchain applications, genetic mapping, and low-cost CBG/CBGA compound production via a joint venture with Biomedican. Further efforts include eliminating over $500,000 in convertible notes and toxic debt from the balance sheet, alongside filings toward SEC reporting compliance and uplisting eligibility as of early 2021, amid positioning for favorable cannabis legislation. No major announcements appear post-2021 through mid-2025, with the company sustaining its focus on real estate investment, IP brands, and infrastructure amid low employee count of two and minimal market capitalization.